Loading ...
Sorry, an error occurred while loading the content.
 

FDA List Serve - World AIDS Day

Expand Messages
  • Klein, Richard M
    You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about
    Message 1 of 2 , Dec 1, 2004
      FDA List Serve - World AIDS Day

      You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

       

      Please do not respond to this message.

      Today is World AIDS Day.

      From the first, isolated reports in 1981, AIDS has grown into a global pandemic.  It affects every corner of the world.  Despite efforts in every nation, the epidemic continues to grow.

      Today the face of AIDS is increasingly young and female. Globally, women account for nearly half the adults living with HIV. The official theme of World AIDS Day this year is Women and Girls and HIV/AIDS, intending to help focus attention and resources on increasing access to prevention and treatment services for women.

      In the United States and other industrialized nations, potent antiviral drugs have dramatically helped people with HIV and AIDS live longer, healthier lives.

      FDA has played a strong role in addressing treatment and prevention from the beginning of the epidemic, including the approval of improved medical treatments, providing access to promising investigational products, helping to prevent the transmission of HIV through regulation of barrier products, protection of the blood supply, and oversight of the development of vaccines (both preventive and therapeutic) and microbicides.

      World AIDS Day commemorates those that have died from AIDS.  It also serves as an opportunity to think about how we can help support the individuals, families, and communities affected by HIV and AIDS, and to renew our commitment to preventing the spread of the disease, developing and delivering more effective treatments, and finding a cure.

      You can find a comprehensive chronology of significant events in FDA's involvement in the fight against HIV on the FDA website at

      http://www.fda.gov/oashi/aids/miles.html

      1981-1990: This decade saw the first report of AIDS and its identification as a retrovirus, approval of the first immunoassay test, approval of the first drug to treat AIDS (AZT), the first drugs for treatment and prevention of certain opportunistic infections, and a mechanism for expanded access to promising therapies prior to approval.

      1991-1994: These years saw the creation of the National Task Force on AIDS Drug Development , large-scale expanded access to pre-approved HIV therapies, and approval of a number of new drugs. Accelerated approval permitted earlier approval of therapies based on surrogate marker activity. The first non blood-based collection system was approved to test for HIV, and a female condom was approved, providing women with a barrier product that didn't rely on a woman's partner to use.

      1995-1999: The final years of the century saw approval of the first protease inhibitor, a new class of drugs for treating HIV, the first home-use AIDS test kit, the first antigen test kit to screen blood donors for HIV-1, and the first viral load test.

      2000-present: In the first years of the 21st century, new formulations and combinations of medications were approved to reduce pill burden. Other approvals: HIV genotyping to help improve treatment outcome, the first nucleic acid test for plasma screening, the first rapid HIV test for use in outreach settings, and the first fusion inhibitor for treating HIV/AIDS.

      _____________________________________________________________________

      In addition, AIDSinfo Launches a New Web Site Design on World AIDS Day 2004

      AIDSinfo is commemorating World AIDS Day 2004, and the web site's second anniversary, with a new web site design.  The new design, which is live today, features a more intuitive layout and consistent navigation. The colorful design, along with improved search functions, makes the site more accessible and useful for health care providers, researchers, patients, families, and users.  The site is also rich in resources because of the significantly increased number of materials available for viewing online, downloading onto Pocket PC/Palm PDAs, and printing from PDFs.

      AIDSinfo provides a wealth of information and resources, including the most up-to-date versions of the HIV/AIDS treatment guidelines and HIV/AIDS-related clinical trial information at www.AIDSinfo.nih.gov

      Richard Klein
      HIV/AIDS Program Director
      Office of Special Health Issues
      Food and Drug Administration


      Kimberly Struble
      Division of Antiviral Drug Products
      Food and Drug Administration

      To UNSUBSCRIBE from this list, or change your e-mail address, please go to
      http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1



       

       

    • Klein, Richard M
      You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about
      Message 2 of 2 , Dec 1, 2005
        FDA List Serve - World AIDS Day

        You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

        To UNSUBSCRIBE from this list, to change your e-mail address, or to subscribe, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

        Please do not reply to this message.
        _______________________________________________

        December 1 is World AIDS Day.


        From the first, isolated reports in 1981, AIDS has grown into a global pandemic.  Despite efforts in every nation, the epidemic continues to grow.  While HIV/AIDS seems to have faded somewhat into the background in the United States, rarely making front page headlines as it has in years past, the epidemic is still present in this country.  There are more than a million people living with HIV and AIDS in the United States today, and an estimated 38 million worldwide.

        AIDS and HIV infection have become part of the American narrative over the past twenty four years.  It is a now part of the fabric of our nation, and that of nations around the world


        FDA has played a strong role in addressing treatment and prevention from the beginning of the epidemic. FDA has made significant contributions to the development and availability of potent antiviral drugs that have dramatically helped people with HIV and AIDS live longer, healthier lives. 


        The agency has played an important role in improving medical treatments, providing access to promising investigational products, helping to prevent the transmission of HIV through regulation of barrier products, protection of the blood supply, and oversight of the development of vaccines (both preventive and therapeutic) and microbicides.


        World AIDS Day commemorates those that have died from AIDS.  It also serves as an opportunity to think about how we can help support the individuals, families, and communities affected by HIV and AIDS, and renew our commitment to preventing the spread of the disease, developing and delivering more effective treatments, and finding a cure.


        You can find a comprehensive chronology of significant events in FDA's involvement in the fight against HIV on the FDA website at

        http://www.fda.gov/oashi/aids/miles.html

        1981-1990: This decade saw the first report of AIDS and its identification as a retrovirus, approval of the first immunoassay test, approval of the first drug to treat AIDS (AZT), the first drugs for treatment and prevention of certain opportunistic infections, and a mechanism for expanded access to promising therapies prior to approval.


        1991-1994: These years saw the creation of the National Task Force on AIDS Drug Development, large-scale expanded access to pre-approved HIV therapies, and approval of a number of new drugs. Accelerated approval permitted earlier approval of therapies based on surrogate marker activity. The first non blood-based collection system was approved to test for HIV, and a female condom was approved, providing women with a barrier product that didn't rely on a woman's partner to use.


        1995-1999: The final years of the century saw approval of the first protease inhibitor, a new class of drugs for treating HIV, the first home-use AIDS test kit, the first antigen test kit to screen blood donors for HIV-1, and the first viral load test.


        2000-present: In the first years of the 21st century, new formulations and combinations of medications were approved to reduce pill burden. Other approvals: HIV genotyping to help improve treatment outcome, the first nucleic acid test for plasma screening, the first rapid HIV test for use in outreach settings, the first fusion inhibitor for treating HIV/AIDS, and the first generic formulations of drugs to treat HIV/AIDS.


        Richard Klein

        HIV/AIDS Program Director

        Office of Special Health Issues

        Food and Drug Administration

        An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html

         

      Your message has been successfully submitted and would be delivered to recipients shortly.